CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
CAR‐T
acute lymphoblastic leukemia
cord blood transplantation
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
21 Apr 2024
21 Apr 2024
Historique:
revised:
05
04
2024
received:
31
01
2024
accepted:
10
04
2024
medline:
22
4
2024
pubmed:
22
4
2024
entrez:
22
4
2024
Statut:
aheadofprint
Résumé
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease. The case report provides insight into the reactivity and persistence of CAR-T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord-derived CAR-T cells.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Giammarco S, Bellesi S, Metafuni E, et al. Cord blood resilience in a patient with relapsing Ph+ B lymphoblastic acute leukemia after hematopoietic stem cell transplantation. Ann Hematol. 2022;101(11):2565‐2566.
Kasakovski D, Xu L, Li Y. T cell senescence and CAR‐T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91.
Shah BD, Ghobadi A, Oluwole OO, et al. KTE‐X19 for relapsed or refractory adult B‐cell acute lymphoblastic leukaemia: phase 2 results of the single‐arm, open‐label, multicentre ZUMA‐3 study. Lancet. 2021;398(10299):491‐502.
Pillai V, Muralidharan K, Meng W, et al. CAR T‐cell therapy is effective for CD19‐dim B‐lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539‐3549.
Pulsipher MA, Han X, Maude SL, et al. Next‐generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66‐81.